CY1123149T1 - Μεθοδος για την παρασκευη φαρμακευτικης συνθεσης που περιλαμβανει παραγωγο κινολινης ή αλας αυτου - Google Patents

Μεθοδος για την παρασκευη φαρμακευτικης συνθεσης που περιλαμβανει παραγωγο κινολινης ή αλας αυτου

Info

Publication number
CY1123149T1
CY1123149T1 CY20201100686T CY201100686T CY1123149T1 CY 1123149 T1 CY1123149 T1 CY 1123149T1 CY 20201100686 T CY20201100686 T CY 20201100686T CY 201100686 T CY201100686 T CY 201100686T CY 1123149 T1 CY1123149 T1 CY 1123149T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
preparation
salt
quinoline derivative
preparing
Prior art date
Application number
CY20201100686T
Other languages
English (en)
Inventor
Yun Lu
Xinhua Zhang
Chenyang Wang
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of CY1123149T1 publication Critical patent/CY1123149T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Η παρούσα εφεύρεση παρέχει μία μέθοδο για την παρασκευή μιας φαρμακευτικής σύνθεσης που περιλαμβάνει ένα παράγωγο κινολίνης ή ένα άλας αυτού. Συγκεκριμένα, η εφεύρεσης παρέχει μία μέθοδο για την παρασκευή μιας φαρμακευτικής σύνθεσης που περιλαμβάνει ένα (R,Ε)-Ν-(4-(3-χλωρο-4-(πυριδιν-2-υλομεθοξυ)φαινυλαμινο)-3-κυανο-7-αιθοξυκινολιν-6-υλ)-3-(1-μεθυλοπυρρολιδιν-2-υλ)-προπεναμίδιο, ή ενός φαρμακολογικά αποδεκτό άλας αυτού. Η μέθοδος περιλαμβάνει τη χρήση ενός παράγοντα διαβροχής που περιλαμβάνει τουλάχιστον έναν οργανικό διαλύτη για μία υγρή κοκκοποίηση σε μία διεργασία παρασκευής της φαρμακευτικής σύνθεσης. Η φαρμακευτική σύνθεση που παρασκευάζεται με τη χρήση της μεθόδου έχει μία ομοιόμορφη κατανομή μεγέθους κόκκων κατά τη διάρκεια της διεργασίας παρασκευής και μία ιδιότητα ταχείας και ομοιόμορφης διαλυτοποίησης.
CY20201100686T 2016-01-27 2020-07-27 Μεθοδος για την παρασκευη φαρμακευτικης συνθεσης που περιλαμβανει παραγωγο κινολινης ή αλας αυτου CY1123149T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610057228 2016-01-27
PCT/CN2017/072156 WO2017129088A1 (zh) 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物的制备方法

Publications (1)

Publication Number Publication Date
CY1123149T1 true CY1123149T1 (el) 2021-10-29

Family

ID=59397365

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100686T CY1123149T1 (el) 2016-01-27 2020-07-27 Μεθοδος για την παρασκευη φαρμακευτικης συνθεσης που περιλαμβανει παραγωγο κινολινης ή αλας αυτου

Country Status (23)

Country Link
US (1) US10722469B2 (el)
EP (1) EP3378479B1 (el)
JP (1) JP6937308B2 (el)
KR (1) KR20180103090A (el)
CN (2) CN107405345A (el)
AU (1) AU2017211737B2 (el)
BR (1) BR112018014544A2 (el)
CA (1) CA3008701A1 (el)
CY (1) CY1123149T1 (el)
DK (1) DK3378479T3 (el)
ES (1) ES2811031T3 (el)
HK (1) HK1243357A1 (el)
HR (1) HRP20201155T1 (el)
HU (1) HUE050255T2 (el)
LT (1) LT3378479T (el)
MX (1) MX2018008862A (el)
PL (1) PL3378479T3 (el)
PT (1) PT3378479T (el)
RS (1) RS60747B1 (el)
RU (1) RU2735807C2 (el)
SI (1) SI3378479T1 (el)
TW (1) TWI720115B (el)
WO (1) WO2017129088A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700086B (zh) * 2017-10-24 2020-08-01 大陸商江蘇恒瑞醫藥股份有限公司 一種含有喹啉衍生物的藥物組合物
KR102511672B1 (ko) * 2018-03-23 2023-03-17 우시 상량 바이오테크놀로지 씨오., 엘티디. 의약 조성물, 그 제조방법 및 사용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100669279B1 (ko) * 2001-12-21 2007-01-16 화이자 프로덕츠 인크. 아지트로마이신의 습식 제립 방법
WO2004032905A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
US20130150386A1 (en) * 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
CN103539783A (zh) 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN116854662A (zh) * 2015-01-30 2023-10-10 生物医学谷探索股份有限公司 C21H22Cl2N4O2的晶型

Also Published As

Publication number Publication date
JP6937308B2 (ja) 2021-09-22
US10722469B2 (en) 2020-07-28
HK1243357A1 (zh) 2018-07-13
CN108938586A (zh) 2018-12-07
US20190054025A1 (en) 2019-02-21
CN107405345A (zh) 2017-11-28
DK3378479T3 (da) 2020-08-03
LT3378479T (lt) 2020-09-10
RS60747B1 (sr) 2020-10-30
WO2017129088A1 (zh) 2017-08-03
PT3378479T (pt) 2020-07-20
RU2735807C2 (ru) 2020-11-09
KR20180103090A (ko) 2018-09-18
SI3378479T1 (sl) 2020-10-30
EP3378479A4 (en) 2018-12-19
TWI720115B (zh) 2021-03-01
BR112018014544A2 (pt) 2018-12-11
PL3378479T3 (pl) 2020-11-02
EP3378479B1 (en) 2020-06-17
TW201726138A (zh) 2017-08-01
CN108938586B (zh) 2021-05-14
MX2018008862A (es) 2018-09-07
EP3378479A1 (en) 2018-09-26
AU2017211737A1 (en) 2018-08-02
JP2019503373A (ja) 2019-02-07
RU2018128416A3 (el) 2020-04-21
CA3008701A1 (en) 2017-08-03
RU2018128416A (ru) 2020-02-27
AU2017211737B2 (en) 2022-04-28
ES2811031T3 (es) 2021-03-10
HRP20201155T1 (hr) 2020-10-30
HUE050255T2 (hu) 2020-11-30

Similar Documents

Publication Publication Date Title
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
CY1123604T1 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4-μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
CY1123149T1 (el) Μεθοδος για την παρασκευη φαρμακευτικης συνθεσης που περιλαμβανει παραγωγο κινολινης ή αλας αυτου
CY1120346T1 (el) Συνδυασμος φαρμακων
CY1124210T1 (el) Τετραϋδροπυρανυλ αμινο-πυρρολοπυριμιδινονη και μεθοδοι χρησης αυτης
CL2016002382A1 (es) Derivados de quinoxalina útiles como moduladores de fgfr quinasa
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
EP3181559B8 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
BR112017012755A2 (pt) compostos de heteroarila de anel fundido e seu uso como inibidores de trk
BR112017024555A2 (pt) moduladores de ccr2
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
BR112016013963A2 (pt) terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
BR112022007612A2 (pt) Inibidores de raf quinases
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
UA113658C2 (xx) Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання
MA54091A (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
CY1125017T1 (el) Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
CY1122170T1 (el) Ορβεπιταντη για τη θεραπευτικη αγωγη χρονιου βηχα
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
BR112016014954A2 (pt) Compostos de benzamida e de nicotinamida e métodos de uso dos mesmos
MA53507A (fr) Nouveau dérivé d'amine hétérocyclique et composition pharmaceutique le comprenant